ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PASG
INTS (39) ATYR (46) BCDA (37) INAB (34) ⌘ Pro Terminal →

Passage Bio Inc. (PASG) — RQD Stock Rating Cockpit

$3.32 -3.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.29

Passage Bio Inc. (PASG) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $11.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PASG Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PASG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Passage Bio Inc. (NASDAQ: PASG) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $3.32 (-3.77% 1D, market cap $11.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PASG ranks #649 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PASG compare to INTS and ATYR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PASG carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INTS (Intensity Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $11.1M) and ATYR (aTyr Pharma Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M). Among the 5-stock peer group, PASG leads on earnings multiple (N/A) while PASG leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PASG?
▼

Per PASG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001787297), Passage Bio Inc. generated $138.0M in revenue (-30.0% YoY), -$45.5M in net income, and -$31.5M in free cash flow against $62.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.29 (-0.87%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (8)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
$21 Bull$3 Base$2 Bear
📬 FREE PASG RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PASG)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY PASG SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$3.64-1.1% Next Q
Q2 (-2Q)
39
Grade E$3.60-6.9% Next Q
Q3 (-1Q)
37
Grade E$3.35-0.9% Next Q
Current
34
Grade E$3.32-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PASG Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PASG currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.23) and Max Pain ($3.49) forces dealer call-delta covering toward $21.00.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PASG• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PASG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
39.430 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $3$3.32H: $20
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on PASG

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (27)

8/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like PASG
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PASG)

  • ✓Walkthrough of PASG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PASG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.35%🛡️ HOLDING TREND SUPPORT
2026-11-03O $3.52H $3.52L $3.32C $3.32VOL 7.2K
RES: $4.67SUP: $3.25SMA50: $4.23SMA200: $6.15
$8.97$7.43$5.89$4.35$2.81RES $4.67SUP $3.25$3.322026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PASG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PASG Butterfly Map → + Track PASG →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -30.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PASG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PASG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PASG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PASG)

Health Care Rank #649 of 1015 ⚔️ INTS vs PASG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PASG vs. INTS, ATYR, BCDA, INAB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Passage Bio Inc. (PASG) ranks #649 by composite RQD confidence (34/100, grade E) and #882 by equity capitalization ($11.1M). Within this direct 5-issuer industry benchmark cohort, PASG leads on earnings valuation at N/A trailing P/E, while PASG leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATYR currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with PASG at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PASG ACTIVE
Passage Bio Inc.
E 34/100 — — -35.0% -3.77% $11.1M Benchmark Subject
INTS
Intensity Therapeutics Inc.
D- 39/100 — — -35.0% +0.88% $11.1M /ints-vs-pasg →
ATYR
aTyr Pharma Inc.
D 46/100 — — -35.0% +27.33% $12.4M /atyr-vs-pasg →
BCDA
BioCardia Inc.
D- 37/100 — — -35.0% +4.75% $13.0M /bcda-vs-pasg →
INAB
IN8bio Inc.
E 34/100 — — -35.0% +0.97% $8.9M /inab-vs-pasg →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001787297 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Passage Bio Inc. (PASG) reported GAAP revenue of $138.0M (-30.0% vs. FY2024 revenue of $197.1M , and -54.5% cumulative change since FY2023) , GAAP net income of -$45.5M, operating cash flow of -$31.5M, and free cash flow of -$31.5M (+34.3% YoY). On the balance sheet, PASG closed FY2025 with $62.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $138.0M -$45.5M -$31.5M -$31.5M $62.3M —
FY2024 (FY) 2024-12-31 $197.1M -$64.8M -$48.0M -$48.0M $102.4M —
FY2023 (FY) 2023-12-31 $303.5M -$102.1M -$78.3M -$78.3M — —

3. PASG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PASG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Passage Bio Inc. (NASDAQ: PASG) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $3.32 (-3.77% 1D, market cap $11.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PASG ranks #649 in composite RQD confidence.

How does PASG compare to INTS and ATYR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PASG carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INTS (Intensity Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $11.1M) and ATYR (aTyr Pharma Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M). Among the 5-stock peer group, PASG leads on earnings multiple (N/A) while PASG leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PASG?

Per PASG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001787297), Passage Bio Inc. generated $138.0M in revenue (-30.0% YoY), -$45.5M in net income, and -$31.5M in free cash flow against $62.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PASG trading relative to its 50-day, 200-day, and 52-week technical levels?

PASG last traded at $3.32 (-3.77% on volume of 11,138 shares), positioning the stock -21.51% below its 50-day simple moving average ($4.23) and -46.02% below its 200-day simple moving average ($6.15). Across its 52-week range of $3.29 to $20.00, PASG sits at the 0.2% percentile with a 14-day RSI of 39.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.91 to $3.73).

Direct Sub-Reports: PASG RQD Cockpit PASG 12M Forecast PASG Earnings & Move PASG Dividends & DRIP PASG Insiders & 13F PASG Whale Options PASG Profit Sankey PASG News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

PASG — Passage Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Passage Bio Inc. (PASG) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.32 (-3.77% 1D, market capitalization $11.1M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Passage Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Passage Bio Inc. (PASG) reported $138.0M in annual revenue (up from $197.1M in FY2024, -30.0% YoY) and -$45.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($303.5M revenue, -$102.1M net income) through FY2025, PASG scaled operating cash flow to -$31.5M and free cash flow to -$31.5M, backed by $62.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.29 – $20.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The sector is Health Care and the industry is Biotechnology: Biological Products (No Diagnostic Substances). Upstream and downstream dependencies, sector correlations beyond beta of 1. The merger-vote timing noted in the news feed is the only near-term event a prospective investor could track against the company's cash position.

  • Key Question #1: Can PASG sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $138.0M and free cash flow of -$31.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PASG's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PASG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Passage Bio Inc. (PASG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PASG Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PASG Bull vs. Bear Conversation Board — What's Your Call at $3.32?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PASG 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PASG:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $4.42 (+28.1%)
📌 Pinned Debate

Balance-sheet pillar scores 10/20 with Altman Z of 2.5 and reported cash of $46.3M in FY 2025, offering some near-term liquidity cushio

Picked up a starter position in PASG in my $100K Virtual Cash book at $3.45. Balance-sheet pillar scores 10/20 with Altman Z of 2.5 and reported cash of $46.3M in FY 2025, offering some near-term liquidity cushion.. Trading inside a $3.29–$20.00 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

SectorRotator 🐂 BULL

@QuantViper Agree on the RQD 34/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.45 and keeping dry powder in case we test $3.21.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $2.76 (-20.0%)
Spot @ $3.45

Zero reported revenue, net losses of -$45.5M in FY 2025, ROIC of -35%, and a whale-flow pillar of 3/20 signal a cash-consuming issuer w

Zero reported revenue, net losses of -$45.5M in FY 2025, ROIC of -35%, and a whale-flow pillar of 3/20 signal a cash-consuming issuer with weak institutional support.. Look at the math on PASG: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $3.04 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%